Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933736 · ClinicalTrials.gov registry record · Early Phase 1
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
A Early Phase 1 study of Glioblastoma Multiforme and Meningioma, sponsored by Nader Sanai.
- Active
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT02933736 is a Early Phase 1 study of Glioblastoma Multiforme and Meningioma that is active but no longer recruiting, run by Nader Sanai. The registered enrollment target is 48 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02933736, a Early Phase 1 study of Glioblastoma Multiforme and Meningioma, is active but no longer recruiting, sponsored by Nader Sanai.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 intervals before brain tumor resection.
Conditions Studied
Interventions
- DRUG Ribociclib
Study Locations (1)
Arizona
- Barrow Brain and Spine - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2027-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933736
The ClinicalTrials.gov registry entry for NCT02933736 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (50% lower). The listed sponsor is Nader Sanai, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Ribociclib is the first listed.
NCT02933736 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02933736 about?
NCT02933736 is a clinical study titled "Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients". In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 inter...
What is the current status of trial NCT02933736?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2016-10-17. Estimated completion is 2027-03.
What conditions does trial NCT02933736 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme, Meningioma.
What interventions are being tested in trial NCT02933736?
The interventions under investigation include: Ribociclib (DRUG).
Who is sponsoring clinical trial NCT02933736?
This trial is sponsored by Nader Sanai, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933736 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
RECRUITING · Early Phase 1
-
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
ACTIVE NOT RECRUITING · Early Phase 1
-
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
ACTIVE NOT RECRUITING · Early Phase 1
-
Study of Pamiparib in Newly Diagnosed and rGBM
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.